Effect of bromocriptine on plasma catecholamines in normal subjects and prolactin-secreting tumor patients
Journal of Endocrinological Investigation
bromocriptine; Plasma catecholamines; prolactinomas
The effect of short term bromocriptine (5 mg/day, 5 days) on plasma epinephrine (E), norepinephrine (NE), dopamine (DA) and prolactin (PRL) was studied in 4 normal women and 6 bearing PRL-secreting tumors. When studied on placebo no significant differences were found between controls and patients in E, NE and DA plasma levels. Bromocriptine induced: a) a 70% decrease in PRL levels in both groups, b) a significant (p < 0.05) decrease in plasma NE levels in the control group, c) no significant change in plasma NE levels in the hyperprolactinemic patients when considered as a group. These results do not indicate that bromocriptine is a useful tool in the diagnosis of defective central dopaminergic regulation since individual responses of the PRL-secreting tumor patients were variable. Nevertheless, the impaired response of the group as a whole may be suggesting an underlying alteration of DA2 receptor activity in these tumor patients. © 1986, Italian Society of Endocrinology (SIE). All rights reserved.
Mancini, A., Barontini, M., Armando, I., Levin, G., Kleiman, A., Razumny, J., & Molocznik, I. (1986). Effect of bromocriptine on plasma catecholamines in normal subjects and prolactin-secreting tumor patients. Journal of Endocrinological Investigation, 9 (3). http://dx.doi.org/10.1007/BF03348104